Vaccination coverage with the pneumococcal and influenza vaccine among persons with chronic diseases in Shanghai, China, 2017

Abstract

Background: Adults with chronic conditions such as heart disease, diabetes, or lung disease are more likely to develop complications from a number of vaccine-preventable diseases, including influenza and pneumonia. In this study, we use the data from a chronic disease management information system in Shanghai to estimate vaccination coverage and characterize predictors of seasonal influenza and 23-valent pneumococcal polysaccharide vaccine (PPSV23) vaccination among people with chronic disease in Shanghai. Methods: The Shanghai Centers for Disease Control and Prevention have information systems related to chronic disease management, hospital records, and immunizations. Data from individuals with hypertension, diabetes and chronic obstructive pulmonary disease (COPD) were abstracted during July 2017. The main outcome was coverage of pneumococcal and influenza vaccination. Vaccination coverage was calculated across demographic groups. Significance in bivariate associations was assessed through Pearson's chi-square tests, and in multivariable models through logistic regression models with a forward stepwise method to select variables. Results: In the sample of 2,531,227 individuals ≥15 years, 22.8% were vaccinated for pneumonia from

Heightened Willingness toward Pneumococcal Vaccination in the Elderly Population in Shenzhen, China: A Cross-Sectional Study during the COVID-19 Pandemic

“…Such a policy had been carried out in multiple cities of China, such as Beijing, Shanghai, and Chengdu. In contrast, a retrospective cohort study during the policy implementation period in Shanghai reported a pneumococcal vaccine coverage of 22.8% among individuals aged over 15 years with chronic diseases [ 12 ]. Moreover, a cross-sectional study involved 235 patients with rheumatic diseases, suggesting none (0.0%) of participants had experience with pneumococcal vaccination [ 18 ].…”

“…At present, two vaccines have been widely used for pneumonia protection, including the 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23), and the latter was approved for application in elderly persons according to Chinese guidelines for vaccination [ 11 ]. However, the vaccination coverage with PPSV23 remains exceptionally low in most areas of mainland China [ 12 ] when compared to Hong Kong [ 13 ] and other developed countries, such as the United States and England, with the pneumococcal vaccination coverage as 61.3% and 69.8%, respectively for older adults [ 1 , 14 ]. Furthermore, the pneumococcal vaccine coverage rates differ in different age groups.…”

Pediatric Intensive Care Unit Admissions for COVID-19: Insights Using State-Level Data

“…The association with state population density makes intuitive sense as urban centers potentiate a rapid spread of an infectious disease, as well as a greater number of global travel routes [ 14 ]. Though it was reported that influenza immunization rates are higher in urban areas [ 15 ], the role of influenza immunization in the COVID-19 transmission requires further investigation as recent studies have described the phenomenon of virus interference in which an immunization against one virus may increase the risk of illness from other viruses [ 16 ]. A recent study by Wolff and colleagues found in a cohort of 6,000 patients that influenza immunization increased the risk of illness from nonpandemic coronavirus (odds ratio of 1.36; 95% confidence interval 1.14 to 1.63, p < 0.01) [ 17 ].…”

Public preference for COVID‐19 vaccines in China: A discrete choice experiment

“…This study showed that urban residents preferred a vaccine with higher effectiveness, whereas rural residents preferred longer protective duration. Although several previous studies have reported low vaccination coverage in rural populations, [47][48][49] none compared the individual vaccination preferences between the rural and the urban areas.…”